-
CB2R Activation Limits Iron-Overload Liver Injury
2026-09-27
Deng and colleagues report that cannabinoid receptor 2 (CB2R) activation reduces iron deposition, oxidative stress, and inflammation in an iron-overload mouse model. Their central mechanistic insight is a two-cell-type response: CB2R signaling suppresses STAT3-dependent hepcidin in hepatocytes while promoting Nrf2/FPN1 signaling in Kupffer cells.
-
Caspase-3/7 Inhibitor I in Apoptosis Workflows
2026-09-26
Use a reversible executioner-caspase inhibitor to test whether caspase-3/7 activity contributes to cell death—not simply accompanies it. A phase-resolved Candida krusei model offers a practical example, with workflow guidance for controls, orthogonal readouts, and troubleshooting.
-
Rucaparib Workflows for DNA Damage Research
2026-09-25
Use Rucaparib (AG-014699) to probe PARP-dependent repair, DNA damage persistence, and radiosensitization in carefully selected cancer models. This practical guide combines a controlled dose-and-radiation workflow with troubleshooting advice and a cautious framework for comparing DNA damage response findings with a recent study of Pol II degradation.
-
Azilsartan Medoxomil and AT1 Receptor Blockade
2026-09-25
This 2017 mini-review examines whether azilsartan medoxomil’s persistent AT1-receptor binding is reflected in its blood-pressure effects compared with other angiotensin receptor blockers. It summarizes receptor-binding, pharmacokinetic, and clinical evidence while highlighting that stronger blood-pressure reduction has not yet established a reduction in cardiovascular mortality.
-
EZ Cap™ CBEmax mRNA (m1Ψ): Evidence & Use
2026-09-24
EZ Cap™ CBEmax mRNA (m1Ψ) is a research-use cytosine base-editor mRNA product listed by APExBIO. A mouse-embryo study found excess variants with BE4, but it did not test R1044, so its results inform assay design rather than establish this product’s performance.
-
Peroxynitrite, ER Stress, and Cardiac I/R Injury
2026-09-24
Liu et al. describe how hyperhomocysteinemia can amplify cardiac microvascular ischemia–reperfusion injury through peroxynitrite-driven ER stress and IP3R-mediated calcium transfer to mitochondria. Their cell and rat models link calcium dysregulation to mitochondrial injury and endothelial necroptosis, while pharmacological IP3R inhibition improved cardiac outcomes in the rat model.
-
Everolimus (RAD001): Growth Arrest vs Cell Death
2026-09-24
Everolimus (RAD001) inhibits mTOR signaling, but a lower viability signal does not by itself reveal whether cells stopped proliferating or died. This guide applies a dual-outcome framework to mTOR experiments, helping researchers choose measurements and interpret exposure-response data more carefully.
-
AMC-Hem Maps Real-Time HO-1 Activity
2026-09-23
The reference study introduces AMC-Hem, a red-shifted aminocoumarin–heme fluorescence probe designed to report heme oxygenase-1 activity in real time. Its application in primary human macrophages and serum revealed spatially localized activity around erythrocyte-containing lysosomes and identified non-transcriptional regulation of HO-1.
-
Right Ventricular-Like Cardiomyocytes from hPSCs
2026-09-22
Saito et al. developed a differentiation strategy that enriches human pluripotent stem cell-derived cardiomyocytes with right ventricular-like characteristics by modifying mesoderm formation during the GiWi cardiac differentiation protocol. The resulting cells showed SHF-associated molecular identity and functional differences from predominantly left ventricular-like cardiomyocytes, creating a useful platform for chamber-specific disease modeling.
-
Streptavidin Magnetic Beads for RNA Pull-Down
2026-09-22
Learn how Benzyl-activated Streptavidin Magnetic Beads can support biotin-dependent RNA pull-down, interaction mapping, and oncology assay development. This article translates the SNORA38B–E2F1–GAB2 signaling study into practical capture and validation decisions without confusing reagent capability with biological proof.
-
Targeted SPP1 Inhibition in Tumor-Associated Myeloid Cells
2026-09-21
The reference study develops a phenotypic strategy for reducing SPP1 expression in tumor-associated macrophages by combining small-molecule screening with TAM-avid nanodelivery. Its lead formulation, CANDI460, lowered SPP1 in cellular and animal models and produced tumor remissions, providing a framework for therapeutically reprogramming tumor myeloid cells rather than broadly depleting them.
-
AMC-Hem Reveals New HO-1 Regulation
2026-09-21
The reference study introduces AMC-Hem, an aminocoumarin-based fluorescent substrate that enables real-time measurement and imaging of heme oxygenase-1 activity in living cells. Its application to human monocyte-derived macrophages linked HO-1 activity to lysosomal regions around phagocytosed erythrocytes and revealed non-transcriptional regulation by two small molecules.
-
Spatially Concentrated ABEs Correct PLP1 Mutations
2026-09-20
The reference study introduces spatially concentrated adenine base editors that improve pathogenic PLP1 correction in oligodendrocytes by locally enriching the TadA* deaminase near genomic targets. Its compact, AAV-compatible design combines stronger on-target editing with reduced transcriptome-wide RNA off-target activity, providing a mechanistic framework for difficult-to-edit myelinating cells.
-
o-Agatoxin IVA and Excitotoxicity in Cortical Neurons
2026-09-19
Lustig, Ahern, and Greenberg tested whether blocking P/Q-type calcium channels with α-agatoxin IVA protects cultured cortical neurons from excitotoxic injury. The toxin failed to reduce injury caused by veratridine, ouabain, or NMDA, showing that inhibition of depolarization-evoked glutamate release does not necessarily translate into neuroprotection.
-
Separating Growth Arrest from Cell Death in Cancer Assays
2026-09-18
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly conflated measurements capture different components of drug response. The work provides a practical framework for separating proliferation arrest from cell killing, improving interpretation of cancer drug screens and preclinical studies.